Similarly, the reactivation of PTPRJ’s PTP activity by blocking ROS has been demonstrated to prolong survival in a murine model of FLT3 ITD–driven myeloproliferative disease (22, 24). Here, PTPRJ is linked to myeloproliferative disorder.